Codexis trades up its manufacturing story with ECOsynthesis scale milestones and a fresh cash cushion
A capital raise, GMP facility progression, and stereochemistry data reset the narrative around enzymatic siRNA production — but the market's patience is still the key variable.
CDXS · Earnings Call · 2026-08-11
A pivot within a pivot
Codexis' second-quarter call was not about a single inflection point but a series of compounding proof points that, taken together, make a stronger case that its siRNA medicine manufacturing platform — ECOsynthesis — is becoming a real commercial contender. The company reported revenue of $14.9 million, down only slightly year-over-year, but the optics were much better than the absolute number. Management framed the quarter as a return to growth in its legacy biocatalysis business, while the ECOsynthesis story advanced on three fronts: new data on stereochemical control, progress with CDMO partners, and the start of construction on a GMP facility.That quote from CSO Stefan Lutz captures the core technical promise. The market has been waiting for ECOsynthesis to move beyond feasibility studies, and the call delivered several markers of that transition. Most concretely, the company has completed small-scale technology transfers with each of its three CDMO partners, and one partner has finished its assessment: “The most advanced of those assessments has been completed and we are in negotiations for a long term commercial contract.” — Britton Jimenez, Senior Vice President, Sales and Marketing · 2026-08-11 This is the nearest thing to a revenue catalyst in the near term, and it links directly to the Starterless ECOsynthesis and stereochemistry control capabilities showcased at TIDES U.S. The company is not just selling an enzyme; it is trying to set a new standard for how siRNA therapeutics are manufactured. Management emphasized that the platform can lower process complexity and reduce downstream purification, a point that should resonate with CDMOs facing capacity constraints.The engineered enzymes that power ECOsynthesis deliver products with defined stereochemical configurations offering users unprecedented control within a scalable oligonucleotide manufacturing process.
Financing and the path to GMP
Codexis' cash position was a key theme. The company ended Q2 with $54.9 million in cash, but a $25 million equity raise two weeks later lifted the pro forma balance to roughly $79.8 million. That gives Codexis runway through 2028, including the planned buildout of its GMP facility. Management explicitly tied the capital to execution: “Our recent successful financing, which closed 2 weeks ago, resulted in a capital raise of $25 million of net proceeds.” — Alison Moore, President and Chief Executive Officer · 2026-08-11 The GMP facility investment — approximately $25 million — is the clearest financial commitment yet to the ECOsynthesis thesis. The company expects to submit a building permit application imminently and has ordered equipment. This is a meaningful shift from earlier conversations where GMP capacity was more of a conceptual option. It also aligns with the broader narrative around the oligonucleotide manufacturing bottleneck; the company cites a 30-fold demand increase by 2035 and a likely capacity crunch within three years. The fundamentals show a company in transition: total revenue is down ~44% from its 2022 peak, but the recent quarter's $14.9 million is within shouting distance of the prior year, and management is guiding to $70–76 million for full-year 2026, implying a heavily back-half-loaded ramp. That guidance, reiterated on the call, looks ambitious given Q1 and Q2 combined were only around $23 million. Yet the company points to improving base business trends and new product approvals — four partner drugs approved in 2026 alone, with a label expansion. The mix shift toward higher-margin products should help: product gross margin hit 73% in Q2, up from 66% in Q1, and the company now expects full-year gross margins in the high 60s.Customer traction and the road ahead
What made this call different from prior quarters was the specificity around customer engagements. Beyond the CDMO progress, management described active conversations with “pioneer siRNA companies” and large biopharma. increase 30 –fold demand is the hook, but the company is careful not to overpromise on timing. In Q&A, Alison Moore acknowledged that the scale-up still has technical hurdles: flow rates, immobilized enzyme performance, and sequence-specific behavior. “We are making material with particular stereo configuration. We are advancing studies to understand the activity opportunities of different configurations.” — Alison Moore, President and Chief Executive Officer · 2026-08-11 That last quote actually came from Alison Moore's response to a question about stereochemistry, and it underscores the company's approach: use technical milestones to keep customers engaged even before commercial contracts are signed. The stock has not yet rewarded the narrative — CDXS is down roughly 25% over the past 90 days and remains about 96% below its 2021 peak. But the fundamental trajectory may finally be turning. The company has a clear catalyst pipeline: the CDMO contract negotiations, TIDES Europe data, and the start of GMP construction. If even one of those converts to a licensing or supply deal, the market could re-rate the story quickly.This is a company that has pivoted once already — from small-molecule enzymes to RNA manufacturing — and is now executing on that pivot. The prior quarter's commentary hinted that ECO would drive growth, but this call provided the concrete evidence: technology transfers completed, a negotiable CDMO contract, and financing in the bank. The remaining question is whether the revenue guidance can be met, but the story is far more tangible than it was a quarter ago.We expect that our current cash will be sufficient to fund our planned operations capital expenditures through 2028 extending our previous cash runway guidance.